Global Cancer Diagnostics Market is expected to reach USD 40.10 billion by 2024 from USD 16.55 billion in 2016, at a CAGR of 11.7% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Cancer diagnostics market has the largest market segment in drug delivery market.
Access Full Report: http://databridgemarketresearch.com/reports/global-cancer-diagnostics-market/
The global cancer diagnostics market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Thermo Fisher Scientific, Inc. dominated the cancer diagnostics market, by platform based accounting for the highest market share in 2016, followed by Illumina, Inc. and Roche Diagnostics. GE Healthcare dominated the cancer diagnostics market, by imaging accounting for the highest market share in 2016, followed by Siemens Healthcare GmbH and Hologic, Inc. Other players in this market include Agilent Technologies, Abbott, Becton, Dickinson and Company, and Koninklijke Philips N.V., among others holds 24.7% of the global cancer diagnostics market in 2016.
Thermo Fisher Scientific Inc,:
Founded in 2006 as Thermo Fisher Scientific, Inc, and head quartered in Massachusetts, U.S. is focused on developing, manufacturing and sales of medical supplies, devices, laboratory equipment and diagnostic products. The company operates through four business segments: laboratory products and services, life sciences and solutions, analytical instruments and specialty diagnostic.
Founded in 1998 and headquartered in San Diego, USA. Illumina, inc. is engaged in the development, manufacturing and market integration for analysis of genetic variation and biological function. The company operates through three business segments, namely research, applied science and clinical. The research segment includes the Molecular Biological research tool, Applied Genomics Solutions, Oncology, Microbial Genomics and Genomics in Drug Development. The Applied Science segment of company offers Forensic Genomics, Commercial Agricultural Applications, Molecular Epidemiology and Biobank Analysis Solution. The clinical segment includes Molecular Diagnostics, Reproductive and Genetic Health, Translational Research and others.
Founded in 1994 and headquartered in Chicago, U.S. GE Healthcare provides transformational medical technologies and services. GE healthcare operates through three business segments healthcare systems, life sciences, and healthcare digital.
Simens Healthcare GmbH:
Founded in 1847 and headquartered in Erlangen, Germany. Siemens Healthcare GmbH is engaged in medical technologies. The company operates through different business segments, such as medical imaging, laboratory diagnostic, point of care testing, healthcare IT services, and clinical specialities & diseases. The clinical specialties & diseases segment includes cardiology, neurology, oncology, surgery, women health and others. In oncology, Siemens Healthcare GmbH provides Imaging, Laboratory Diagnostics, Virtual MR/Ultrasound Guidance for TRUS Assisted Prostate Biopsy and others.
Global Cancer Diagnostics Market – Industry Trends - Forecast to 2026
North America Cancer Diagnostics Market – Industry Trends and Forecast to 2026
Europe Cancer Diagnostics Market – Industry Trends and Forecast to 2026
APAC Cancer Diagnostics Market – Industry Trends and Forecast to 2024
Global Noninvasive Cancer Diagnostics Market– Industry Trends and Forecast to 2025